<code id='22382EF3C2'></code><style id='22382EF3C2'></style>
    • <acronym id='22382EF3C2'></acronym>
      <center id='22382EF3C2'><center id='22382EF3C2'><tfoot id='22382EF3C2'></tfoot></center><abbr id='22382EF3C2'><dir id='22382EF3C2'><tfoot id='22382EF3C2'></tfoot><noframes id='22382EF3C2'>

    • <optgroup id='22382EF3C2'><strike id='22382EF3C2'><sup id='22382EF3C2'></sup></strike><code id='22382EF3C2'></code></optgroup>
        1. <b id='22382EF3C2'><label id='22382EF3C2'><select id='22382EF3C2'><dt id='22382EF3C2'><span id='22382EF3C2'></span></dt></select></label></b><u id='22382EF3C2'></u>
          <i id='22382EF3C2'><strike id='22382EF3C2'><tt id='22382EF3C2'><pre id='22382EF3C2'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:explore    - browse:3123
          Merck's logo on an office building against the blue sky — coverage from STAT
          Adobe

          LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline. 

          Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.  

          advertisement

          EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time